These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 19238112)
1. An elevated value of high mobility group box 1 is a potential marker for poor response to high-dose of intravenous immunoglobulin treatment in patients with Kawasaki syndrome. Eguchi T; Nomura Y; Hashiguchi T; Masuda K; Arata M; Hazeki D; Ueno K; Nishi J; Kawano Y; Maruyama I Pediatr Infect Dis J; 2009 Apr; 28(4):339-41. PubMed ID: 19238112 [TBL] [Abstract][Full Text] [Related]
2. High mobility group box-1 protein in patients with suspected community-acquired infections and sepsis: a prospective study. Gaïni S; Pedersen SS; Koldkjaer OG; Pedersen C; Møller HJ Crit Care; 2007; 11(2):R32. PubMed ID: 17346334 [TBL] [Abstract][Full Text] [Related]
3. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Kobayashi T; Inoue Y; Takeuchi K; Okada Y; Tamura K; Tomomasa T; Kobayashi T; Morikawa A Circulation; 2006 Jun; 113(22):2606-12. PubMed ID: 16735679 [TBL] [Abstract][Full Text] [Related]
4. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. Fukunishi M; Kikkawa M; Hamana K; Onodera T; Matsuzaki K; Matsumoto Y; Hara J J Pediatr; 2000 Aug; 137(2):172-6. PubMed ID: 10931407 [TBL] [Abstract][Full Text] [Related]
5. High mobility group box 1 (HMGB1) and macrophage migration inhibitory factor (MIF) in Kawasaki disease. Hoshina T; Kusuhara K; Ikeda K; Mizuno Y; Saito M; Hara T Scand J Rheumatol; 2008; 37(6):445-9. PubMed ID: 18720262 [TBL] [Abstract][Full Text] [Related]
6. Assessment of intravenous immunoglobulin non-responders in Kawasaki disease. Hwang JY; Lee KY; Rhim JW; Youn YS; Oh JH; Han JW; Lee JS; Burgner D Arch Dis Child; 2011 Nov; 96(11):1088-90. PubMed ID: 20551193 [TBL] [Abstract][Full Text] [Related]
7. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. Uehara R; Belay ED; Maddox RA; Holman RC; Nakamura Y; Yashiro M; Oki I; Ogino H; Schonberger LB; Yanagawa H Pediatr Infect Dis J; 2008 Feb; 27(2):155-60. PubMed ID: 18174868 [TBL] [Abstract][Full Text] [Related]
8. Significant increase of serum high-mobility group box chromosomal protein 1 levels in patients with severe acute pancreatitis. Yasuda T; Ueda T; Takeyama Y; Shinzeki M; Sawa H; Nakajima T; Ajiki T; Fujino Y; Suzuki Y; Kuroda Y Pancreas; 2006 Nov; 33(4):359-63. PubMed ID: 17079940 [TBL] [Abstract][Full Text] [Related]
9. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. Egami K; Muta H; Ishii M; Suda K; Sugahara Y; Iemura M; Matsuishi T J Pediatr; 2006 Aug; 149(2):237-40. PubMed ID: 16887442 [TBL] [Abstract][Full Text] [Related]
10. New immunological serum markers in bacteraemia: anti-inflammatory soluble CD163, but not proinflammatory high mobility group-box 1 protein, is related to prognosis. Gaïni S; Pedersen SS; Koldkaer OG; Pedersen C; Moestrup SK; Møller HJ Clin Exp Immunol; 2008 Mar; 151(3):423-31. PubMed ID: 18190604 [TBL] [Abstract][Full Text] [Related]
11. Non-classical Kawasaki disease in a 2 month old infant. Hartmann I; Weiss K; Bistritzer T; Baram S; Goldman M Isr Med Assoc J; 2006 Aug; 8(8):581-2. PubMed ID: 16958253 [No Abstract] [Full Text] [Related]
12. Analysis of Kawasaki disease showing elevated antibody titres of Yersinia pseudotuberculosis. Tahara M; Baba K; Waki K; Arakaki Y Acta Paediatr; 2006 Dec; 95(12):1661-4. PubMed ID: 17129979 [TBL] [Abstract][Full Text] [Related]
13. Platelet vascular endothelial growth factor is a useful predictor for prognosis in Kawasaki syndrome. Ueno K; Nomura Y; Hashiguchi T; Masuda K; Morita Y; Hazeki D; Eguchi T; Maruyama I; Kawano Y Br J Haematol; 2010 Jan; 148(2):285-92. PubMed ID: 19793253 [TBL] [Abstract][Full Text] [Related]
14. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study]. DU ZD; Zhao D; DU JB; Lu S; Yi JM; Hou AC; Zhou ZS; Ding GF; Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3119-21. PubMed ID: 18269869 [TBL] [Abstract][Full Text] [Related]
15. Kawasaki disease with lymphadenopathy and fever as sole initial manifestations. Kubota M; Usami I; Yamakawa M; Tomita Y; Haruta T J Paediatr Child Health; 2008 Jun; 44(6):359-62. PubMed ID: 18476929 [TBL] [Abstract][Full Text] [Related]
16. High-dose intravenous immunoglobulin downregulates the activated levels of inflammatory indices except erythrocyte sedimentation rate in acute stage of Kawasaki Disease. Lee KY; Lee HS; Hong JH; Han JW; Lee JS; Whang KT J Trop Pediatr; 2005 Apr; 51(2):98-101. PubMed ID: 15677370 [TBL] [Abstract][Full Text] [Related]
17. Factors associated with serum high mobility group box 1 (HMGB1) levels in a general population. Fukami A; Adachi H; Yamagishi S; Matsui T; Ueda S; Nakamura K; Enomoto M; Otsuka M; Kumagae S; Nanjo Y; Kumagai E; Esaki E; Murayama K; Hirai Y; Imaizumi T Metabolism; 2009 Dec; 58(12):1688-93. PubMed ID: 19616266 [TBL] [Abstract][Full Text] [Related]
18. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease. Lee TJ; Kim KH; Chun JK; Kim DS Yonsei Med J; 2008 Oct; 49(5):714-8. PubMed ID: 18972590 [TBL] [Abstract][Full Text] [Related]
19. Utility of ferritin as a predictor of the patients with Kawasaki disease refractory to intravenous immunoglobulin therapy. Yamamoto N; Sato K; Hoshina T; Kojiro M; Kusuhara K Mod Rheumatol; 2015; 25(6):898-902. PubMed ID: 25849851 [TBL] [Abstract][Full Text] [Related]